InspireMD announced the issuance of a key U.S. patent covering its SwitchGuard Neuroprotection System and plans to submit an Investigational Device Exemption to the FDA in 2024 for a clinical trial.
AI Assistant
INSPIREMD INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.